Breast Cancer Trial, Recruiting NCT07122713 Sponsor: Alexander Stessin Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07122713
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with invasive breast cancer confirmed by a biopsy, including lobular, ductal, or related types
  • People whose breast cancer falls within certain size and spread categories, based on imaging or physical examination (ranging from smaller tumours with no lymph node involvement to larger tumours with some spread to nearby lymph nodes, including some cases where cancer may have spread to other parts of the body)
  • People whose cancer cannot be removed by surgery, who have been assessed by a surgeon as not being a good candidate for surgery, or who have chosen not to have surgery
  • People who are expected to live for more than 6 months
  • Women of childbearing age who have a negative pregnancy test at the time treatment begins

Who may not be able to join:

  • People who are currently receiving certain systemic cancer treatments — note that hormone therapies, HER2-targeted therapies, and immunotherapies are allowed and would not prevent participation (confirm with trial site)
  • People who have previously had radiation therapy to the same breast or the nearby lymph node areas on the same side
  • People whose body size or physical characteristics make it not possible to plan or deliver the study treatment safely (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexander Stessin, MD PhD, Stony Brook University Hospital

Phone: 631-728-7425

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Alexander Stessin
Registry
ClinicalTrials.gov
Start date
8 December 2025
Est. completion
30 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Treatment Safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov